• Je něco špatně v tomto záznamu ?

Whole blood concentrations of fingolimod and its pharmacologically active metabolite fingolimod phosphate obtained during routine health care of patients with multiple sclerosis

I. Kacirova, ZK. Kusnirikova, V. Pesakova, P. Hradilek, H. Brozmanova, M. Grundmann

. 2025 ; 93 (-) : 106246. [pub] 20241221

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25010427

BACKGROUND: Fingolimod is a first-in-class, orally administered drug indicated for the treatment of relapsing-remitting multiple sclerosis. It acts as an immunomodulator, is classified as a "disease-modifying therapy", and its main mechanism of action is the modulation of sphingosine-1-phosphate receptors. In this prospective pilot study, whole blood concentrations of fingolimod and fingolimod phosphate obtained during routine health care were measured. In this study, we aimed to determine whether therapeutic monitoring of fingolimod and fingolimod phosphate concentrations can help personalise pharmacotherapy for patients with multiple sclerosis. METHOD: The study group consisted of 73 patients treated with oral fingolimod (0.5 mg) once daily. Blood samples were collected between July 2021 and January 2022. The whole blood concentrations of fingolimod and fingolimod phosphate were analysed using ultra-high-performance liquid chromatography-tandem mass spectrometry. The relationship between the measured concentrations and the absolute peripheral blood lymphocyte count was evaluated. RESULTS: Fingolimod concentrations ranged from 0.61 to 6.21 μg/L, and fingolimod phosphate concentrations from 0.48 to 4.28 μg/L. Significantly higher concentrations of the active metabolite, fingolimod phosphate, and a significantly higher fingolimod phosphate/fingolimod concentration ratio were observed in women. The sum of fingolimod and fingolimod phosphate concentrations was significantly higher in the subgroup of patients with a lower absolute peripheral blood lymphocyte count. CONCLUSION: Although all patients were treated with the same dose of fingolimod (0.5 mg orally daily), a 10-fold difference was observed in the achieved whole blood concentrations of fingolimod and fingolimod phosphate. This wide inter-individual variability may lead to potential toxicity or suboptimal concentrations, with the risk of further deterioration in the clinical condition of patients with multiple sclerosis. Therefore, fingolimod is a suitable candidate for therapeutic drug monitoring, including monitoring patient adherence to treatment.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25010427
003      
CZ-PrNML
005      
20250429135420.0
007      
ta
008      
250415e20241221ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.msard.2024.106246 $2 doi
035    __
$a (PubMed)39729901
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Kacirova, Ivana $u Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava; Department of Clinical Pharmacology, Institute of Laboratory Medicine, University Hospital Ostrava, Czech Republic
245    10
$a Whole blood concentrations of fingolimod and its pharmacologically active metabolite fingolimod phosphate obtained during routine health care of patients with multiple sclerosis / $c I. Kacirova, ZK. Kusnirikova, V. Pesakova, P. Hradilek, H. Brozmanova, M. Grundmann
520    9_
$a BACKGROUND: Fingolimod is a first-in-class, orally administered drug indicated for the treatment of relapsing-remitting multiple sclerosis. It acts as an immunomodulator, is classified as a "disease-modifying therapy", and its main mechanism of action is the modulation of sphingosine-1-phosphate receptors. In this prospective pilot study, whole blood concentrations of fingolimod and fingolimod phosphate obtained during routine health care were measured. In this study, we aimed to determine whether therapeutic monitoring of fingolimod and fingolimod phosphate concentrations can help personalise pharmacotherapy for patients with multiple sclerosis. METHOD: The study group consisted of 73 patients treated with oral fingolimod (0.5 mg) once daily. Blood samples were collected between July 2021 and January 2022. The whole blood concentrations of fingolimod and fingolimod phosphate were analysed using ultra-high-performance liquid chromatography-tandem mass spectrometry. The relationship between the measured concentrations and the absolute peripheral blood lymphocyte count was evaluated. RESULTS: Fingolimod concentrations ranged from 0.61 to 6.21 μg/L, and fingolimod phosphate concentrations from 0.48 to 4.28 μg/L. Significantly higher concentrations of the active metabolite, fingolimod phosphate, and a significantly higher fingolimod phosphate/fingolimod concentration ratio were observed in women. The sum of fingolimod and fingolimod phosphate concentrations was significantly higher in the subgroup of patients with a lower absolute peripheral blood lymphocyte count. CONCLUSION: Although all patients were treated with the same dose of fingolimod (0.5 mg orally daily), a 10-fold difference was observed in the achieved whole blood concentrations of fingolimod and fingolimod phosphate. This wide inter-individual variability may lead to potential toxicity or suboptimal concentrations, with the risk of further deterioration in the clinical condition of patients with multiple sclerosis. Therefore, fingolimod is a suitable candidate for therapeutic drug monitoring, including monitoring patient adherence to treatment.
650    _2
$a lidé $7 D006801
650    12
$a fingolimod hydrochlorid $x krev $x aplikace a dávkování $x farmakologie $7 D000068876
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a dospělí $7 D000328
650    _2
$a pilotní projekty $7 D010865
650    12
$a imunosupresiva $x krev $x aplikace a dávkování $7 D007166
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prospektivní studie $7 D011446
650    _2
$a monitorování léčiv $x metody $7 D016903
650    _2
$a relabující-remitující roztroušená skleróza $x farmakoterapie $x krev $7 D020529
650    _2
$a tandemová hmotnostní spektrometrie $7 D053719
650    _2
$a roztroušená skleróza $x farmakoterapie $x krev $7 D009103
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kusnirikova, Zuzana Krska $u Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava; Department of Children Neurology, Department of Neurology, University Hospital Ostrava, Czech Republic. Electronic address: zuzana.kusnirikova@fno.cz
700    1_
$a Pesakova, Veronika $u Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava; Department of Clinical Pharmacology, Institute of Laboratory Medicine, University Hospital Ostrava, Czech Republic
700    1_
$a Hradilek, Pavel $u Department of Neurology, University Hospital Ostrava, Czech Republic; Department of Clinical Neurosciences, Faculty of Medicine, University of Ostrava, Czech Republic
700    1_
$a Brozmanova, Hana $u Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava; Department of Clinical Pharmacology, Institute of Laboratory Medicine, University Hospital Ostrava, Czech Republic
700    1_
$a Grundmann, Milan $u Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava; Department of Clinical Pharmacology, Institute of Laboratory Medicine, University Hospital Ostrava, Czech Republic
773    0_
$w MED00188780 $t Multiple sclerosis and related disorders $x 2211-0356 $g Roč. 93 (20241221), s. 106246
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39729901 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429135415 $b ABA008
999    __
$a ok $b bmc $g 2311653 $s 1247508
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 93 $c - $d 106246 $e 20241221 $i 2211-0356 $m Multiple sclerosis and related disorders $n Mult Scler Relat Disord $x MED00188780
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Možnosti archivace